Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ociperlimab + Tislelizumab With Concurrent Chemoradiotherapy in Limited-stage Small Cell Lung Cancer
CTR20211531Phase 2Completed
- Sponsor
- BeiGene
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ociperlimab, tislelizumab in small cell lung cancer (SCLC), sponsored by BeiGene. Started Jul 2021; status: completed.
02
Drugs
ociperlimabtislelizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20211531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211531.